BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...

NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate ...

3,4 Lecanemab also met all key secondary endpoints, including greater reductions in amyloid burden on positron-emission tomography (PET) and more favorable outcomes on scales such as the AD ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory ...

All key secondary endpoints also showed highly statistically significant results compared with placebo and in the amyloid PET sub-study treatment with lecanemab showed statistically significant ...

Lecanemab, for example, slows the progression of the disease ... This requires undergoing expensive or invasive procedures such as PET scans and lumbar punctures, notwithstanding the eyewatering costs ...

While the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) is currently reviewing donanemab, it has already approved lecanemab ... Expensive PET scans are required to identify ...